SCHEMBL1864641

SCHEMBL1864641

C=CC(=O)Nc1cc(C)ccc1OCOCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ TGM2 P21980 1/20 0.43
▸ MAPK3 P27361 2/20 0.43
▸ FGFR1 P11362 2/20 0.42
▸ FGFR4 P22455 2/20 0.42
▸ CREBBP Q92793 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1867906 0.90 CYP1A2 (0.43) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL16123260 0.89 CREBBP (0.51) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL409556 0.83 LMNA (0.54) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL10027973 0.79 KMT2A (0.55) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL1862565 0.74 FGFR4 (0.41) MAPTLMNACYP2C9CYP2C19TGM2
SCHEMBL18256266 0.74 TGM2 (0.59) SMN1; SMN2MAPTMEN1KMT2ACYP1A2
SCHEMBL31162390 0.73 TGM2 (0.58) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL21894170 0.73 TGM2 (0.58) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL14098226 0.72 CYP1A2 (0.65) SMN1; SMN2RAB9AMAPTMEN1LMNA
SCHEMBL3870279 0.71 GAA (0.67) SMN1; SMN2RAB9AMAPTMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939241-B2 (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2011-05-10 — — US disclosed
US-7939241-B2 (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2011-05-10 — — US disclosed
US-20090068587-A1 (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2009-03-12 — — US disclosed
US-20090068587-A1 (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068587-A1 (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method MMAB, DNMT3A, MAT1A SMN1; SMN2 3987/4885RAB9A 2251/4885MAPT 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback